Fig. 4
Immunogenicity of rPRV-VP2-IL6 in mice. Five groups of 25 Balb/c mice received injection of 100 μL of solution containing either with 5log10 TCID50 of rPRV-VP2-IL6, rPRV-VP2-EGFP, PRV HB98, PPV vaccine or DMEM at both week 0 and week 4. Sera were collected on weeks 0, 2, 4, 6, 8 after the initial immunization and 5 mice were sacrificed at week 8 for lymphocyte proliferation assay. a Anti- PPV antibodies determined by ELISA. b PPV specific lymphocyte proliferation assay. Values are expressed as mean counts ±standard error. Statistically significant differences (P < 0.05) are indicated by * or **